LGALS3 and non-small cell lung carcinoma: A preclinical study in two NSCLC mouse models showed that the combination of an orally active Gal-3 antagonist (GB1107) with blockade of PD-L1 boosts tumor immune infiltration, reducing lung adenocarcinoma growth and blocking metastasis [90].